Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Lymphoma

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 55 articles:
HTML format



Single Articles


    February 2024
  1. STAMMLER R, Ta VA, Cohen E, Ram-Wolff C, et al
    Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma.
    Br J Dermatol. 2024 Feb 23:ljae085. doi: 10.1093.
    PubMed    


  2. JUNG JM, Cho HS, Kim GH, Won CH, et al
    Psoriasiform mycosis fungoides: a clinical and prognostic retrospective cohort study.
    Br J Dermatol. 2024;190:432-434.
    PubMed    


    January 2024
  3. TRUM NA, Chen L, Zain J, Rosen ST, et al
    Significant survival disparity in Black patients with cutaneous lymphoma: a retrospective cohort study.
    Br J Dermatol. 2024 Jan 29:ljae039. doi: 10.1093.
    PubMed    


    October 2023

  4. Multiple skin lesions, especially on the legs, predict a poorer prognosis in skin lymphoma with large tumour cells.
    Br J Dermatol. 2023;189:e98.
    PubMed    



  5. The effect of extracorporeal photopheresis on cytokines released by leukaemic cutaneous T-cell lymphoma.
    Br J Dermatol. 2023;189:e97.
    PubMed    


    September 2023
  6. WEINER D, Ly A, Talluru S, Munjal A, et al
    Efficacy of single-agent chemotherapy with pegylated liposomal doxorubicin or gemcitabine in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma.
    Br J Dermatol. 2023 Sep 1:ljad311. doi: 10.1093.
    PubMed    


    August 2023
  7. MIYAGAKI T, Inoue N, Kamijo H, Boki H, et al
    Prognostic factors for primary cutaneous anaplastic large cell lymphoma: a multicenter retrospective study from Japan.
    Br J Dermatol. 2023 Aug 4:ljad266. doi: 10.1093.
    PubMed     Abstract available


    July 2023
  8. PILERI A, Pimpinelli N
    The role of the immune system in cutaneous T-cell lymphoma, an area requiring more investigation.
    Br J Dermatol. 2023 Jul 24:ljad255. doi: 10.1093.
    PubMed    



  9. An oncogene-targeted therapy for Merkel cell carcinoma.
    Br J Dermatol. 2023;189:e33.
    PubMed    


  10. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2023;189:53-61.
    PubMed     Abstract available


  11. TSAI YC, Schlaepfer T, Ignatova D, Chang YT, et al
    Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in leukaemic cutaneous T-cell lymphoma patients.
    Br J Dermatol. 2023 Jul 6:ljad220. doi: 10.1093.
    PubMed     Abstract available


    May 2023
  12. ALONSO-ALONSO R, Rodriguez M, Garcia-Diaz N, Tomas-Roca L, et al
    NanoString analysis of mycosis fungoides reveals individual molecular identity.
    Br J Dermatol. 2023;188:812-814.
    PubMed    


  13. PETERKNECHT E, Scarisbrick J
    Skin Swabs in the Skin Lymphoma Clinic - From Swab to Treatment.
    Br J Dermatol. 2023 May 13:ljad160. doi: 10.1093.
    PubMed    


    March 2023
  14. FAN K, Srinivas N, Kubat L, Gravemeyer J, et al
    B-cell lymphoma extra-large (Bcl-xL) is a promising drug target in Merkel cell carcinoma.
    Br J Dermatol. 2023 Mar 30:ljad099. doi: 10.1093.
    PubMed     Abstract available


    February 2023
  15. BROWN-KORSAH JB, Omar D, Wang X, Taylor SC, et al
    Factors contributing to time to chemotherapy, immunotherapy and radiation for patients with mycosis fungoides in the United States National Cancer Database.
    Br J Dermatol. 2023;188:299-301.
    PubMed    


    January 2023
  16. OYMANNS M, Daum-Marzian M, Bellm A, Elsayad K, et al
    Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.
    Br J Dermatol. 2023;188:145-146.
    PubMed    


    November 2022
  17. BONTOUX C, de Masson A, Thonnart N, Ram-Wolff C, et al
    Large-cell transformation is an independent poor prognostic factor in Sezary syndrome: analysis of 117 cases.
    Br J Dermatol. 2022;187:815-817.
    PubMed    


    August 2022
  18. KEMPF W
    Follicular T helper cells and cutaneous T-cell lymphomas.
    Br J Dermatol. 2022 Aug 31. doi: 10.1111/bjd.21839.
    PubMed    



  19. Better understanding about the severity of disease in cutaneous T-cell lymphoma from studying immune checkpoint receptors.
    Br J Dermatol. 2022;187:e69-e76.
    PubMed    


  20. DI RAIMONDO C, Rubio-Gonzalez B, Palmer J, Weisenburger DD, et al
    Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sezary syndrome: association with disease stage and clinical outcome.
    Br J Dermatol. 2022;187:234-243.
    PubMed     Abstract available


  21. JIANG TT, Kruglov O, Geskin L, Akilov OE, et al
    Repetitive expanded T-cell receptor clonotypes impart the classic T helper 2 Sezary cell phenotype.
    Br J Dermatol. 2022;187:265-267.
    PubMed     Abstract available


  22. BUECHLER CR, Sagher E, Tisack A, Jacobsen G, et al
    Demographic factors and disparate outcomes in mycosis fungoides: retrospective analysis of a racially diverse 440-patient cohort from Detroit, Michigan, USA.
    Br J Dermatol. 2022;187:246-248.
    PubMed    


    July 2022
  23. WANG L, Rocas D, Dalle S, Sako N, et al
    Primary cutaneous peripheral T-cell lymphomas with a T follicular helper phenotype: An integrative clinical, pathological, and molecular case series study.
    Br J Dermatol. 2022 Jul 27. doi: 10.1111/bjd.21791.
    PubMed     Abstract available


  24. ROCCUZZO G, Fava P, Avallone G, Aquino C, et al
    Time to next treatment and safety assessment in Cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21772.
    PubMed    


  25. WANG J, Ram-Wolff C, Dobos G, Al Hage J, et al
    Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides.
    Br J Dermatol. 2022;187:129-131.
    PubMed    


    June 2022
  26. BATTESTI G, Ram-Wolff C, Dobos G, Aubin F, et al
    Granulomatous slack skin: clinical characteristics, prognosis, and response to therapy. A study from the Cutaneous Lymphoma French Study Group.
    Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21699.
    PubMed    


  27. ROELENS M, de Masson A, Andrillon A, Ram-Wolff C, et al
    Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sezary syndrome.
    Br J Dermatol. 2022;186:1010-1025.
    PubMed     Abstract available


    May 2022
  28. MARTIN-MORO F, Martin-Rubio I, Garcia-Vela JA
    TRBC1 expression assessed by flow cytometry as a novel marker of clonality in cutaneous alphabeta T-cell lymphomas with peripheral blood involvement.
    Br J Dermatol. 2022 May 23. doi: 10.1111/bjd.21678.
    PubMed    


  29. MITTELDORF C
    Multistaining for a better understanding of lymphoma biology.
    Br J Dermatol. 2022 May 4. doi: 10.1111/bjd.21590.
    PubMed    


    March 2022
  30. DOBOS G, Assaf C
    Transcriptomic changes during stage progression of mycosis fungoides: from translational analyses to their potential clinical implications.
    Br J Dermatol. 2022;186:387-388.
    PubMed    


  31. XIAO MZX, Hennessey D, Iyer A, O'Keefe S, et al
    Transcriptomic changes during stage progression of mycosis fungoides.
    Br J Dermatol. 2022;186:520-531.
    PubMed     Abstract available


    February 2022
  32. VERMEER MH, Moins-Teisserenc H, Bagot M, Quaglino P, et al
    Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardised approach.
    Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21053.
    PubMed     Abstract available


  33. FALKENHAIN-LOPEZ D, Fulgencio-Barbarin J, Puerta-Pena M, Montero-Menarguez J, et al
    Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides.
    Br J Dermatol. 2022;186:363-365.
    PubMed    


    January 2022
  34. KEMPF W, Petrella T, Willemze R, Jansen P, et al
    Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations - Results of an EORTC Cutaneous Lymphoma Group Workshop.
    Br J Dermatol. 2022 Jan 5. doi: 10.1111/bjd.20973.
    PubMed     Abstract available


  35. BLANCHARD G, Guenova E
    Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma.
    Br J Dermatol. 2022;186:15-16.
    PubMed    


    November 2021
  36. PAPADAVID E, Kapniari E, Pappa V, Nikolaou V, et al
    Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sezary syndrome with variable CD30 positivity.
    Br J Dermatol. 2021;185:1035-1044.
    PubMed     Abstract available


  37. MOYAL L, Arkin C, Gorovitz-Haris B, Querfeld C, et al
    Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden.
    Br J Dermatol. 2021;185:999-1012.
    PubMed     Abstract available


    October 2021
  38. HENDERSON BERG MH, Davison K, Popradi G
    Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: A single-centre retrospective review.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20786.
    PubMed     Abstract available


    September 2021
  39. POSPISCHIL I, Guenova E
    Mycosis fungoides-derived exosomes and their microRNA-1246 cargo: a message from the skin.
    Br J Dermatol. 2021 Sep 14. doi: 10.1111/bjd.20695.
    PubMed    


    August 2021
  40. TRUM NA, Zain J, Martinez XU, Parekh V, et al
    Mogamulizumab Efficacy is Underscored by its Associated Rash that Mimics Cutaneous T-cell Lymphoma: A Retrospective Single-Centre Case Series.
    Br J Dermatol. 2021 Aug 24. doi: 10.1111/bjd.20708.
    PubMed     Abstract available


  41. HODAK E
    Is lymph node core-needle biopsy an alternative to excisional biopsy for the accurate staging of mycosis fungoides/Sezary syndrome and predicting the survival of patients?
    Br J Dermatol. 2021;185:251-252.
    PubMed    


  42. ORTIZ-ROMERO PL
    The time for new biomarkers in mycosis fungoides/Sezary syndrome is here.
    Br J Dermatol. 2021;185:250-251.
    PubMed    


  43. OTTEVANGER R, de Bruin DT, Willemze R, Jansen PM, et al
    Incidence of mycosis fungoides and Sezary syndrome in the Netherlands between 2000 and 2020.
    Br J Dermatol. 2021;185:434-435.
    PubMed    


  44. CALVANI J, de Masson A, de Margerie-Mellon C, de Kerviler E, et al
    Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sezary syndrome.
    Br J Dermatol. 2021;185:419-427.
    PubMed     Abstract available


  45. DOBOS G, De Cevins C, Ly Ka So S, Jean-Louis F, et al
    The value of five blood markers in differentiating mycosis fungoides and Sezary syndrome: a validation cohort.
    Br J Dermatol. 2021;185:405-411.
    PubMed     Abstract available


    July 2021
  46. GAMBICHLER T, Boms S, Hessam S, Tischoff I, et al
    Primary cutaneous anaplastic large cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination.
    Br J Dermatol. 2021 Jul 6. doi: 10.1111/bjd.20630.
    PubMed     Abstract available


    June 2021
  47. SKAYEM C, Beylot-Barry M, de Masson A, Dereure O, et al
    Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous T-cell lymphoma: nine cases.
    Br J Dermatol. 2021 Jun 15. doi: 10.1111/bjd.20580.
    PubMed     Abstract available


    May 2021
  48. JONAK C, Alkon N, Rindler K, Rojahn TB, et al
    Single-cell RNAseq profiling in a patient with discordant primary cutaneous B and T cell lymphoma reveals micromilieu-driven immune skewing.
    Br J Dermatol. 2021 May 21. doi: 10.1111/bjd.20512.
    PubMed     Abstract available


  49. ZIMMERMANN C, Boisson M, Ram-Wolff C, Sadoux A, et al
    Diagnostic performance of high throughput sequencing of the T-cell receptor beta gene for the diagnosis of cutaneous T-cell lymphoma.
    Br J Dermatol. 2021 May 3. doi: 10.1111/bjd.20432.
    PubMed     Abstract available


  50. MOLLOY K, Vico C, Ortiz-Romero PL, Scarisbrick JJ, et al
    Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sezary syndrome.
    Br J Dermatol. 2021;184:978-981.
    PubMed    


    April 2021
  51. PORCU P, Nikbakht N
    New insights on treatment utilization and outcomes in early-stage mycosis fungoides.
    Br J Dermatol. 2021;184:594-595.
    PubMed    


    March 2021
  52. HODAK E, Sherman S, Papadavid E, Bagot M, et al
    Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study.
    Br J Dermatol. 2021;184:524-531.
    PubMed     Abstract available


    August 2020
  53. D'INCAN M, Ingen-Housz-Oro S, Beylot-Barry M, Joly P, et al
    Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas.
    Br J Dermatol. 2020 Aug 18. doi: 10.1111/bjd.19495.
    PubMed     Abstract available


    May 2020
  54. DANGIEN A, Ram-Wolff C, Brice P, Battistella M, et al
    Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.
    Br J Dermatol. 2020 May 14. doi: 10.1111/bjd.19220.
    PubMed     Abstract available


    February 2020
  55. HWANG S, Johnson A, Fabbro S, Hastings J, et al
    Topical imiquimod monotherapy for indolent primary cutaneous B-cell lymphomas (PCBCL): a single-institution experience.
    Br J Dermatol. 2020 Feb 20. doi: 10.1111/bjd.18961.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.